Boston Scientific (BSX) Stock Plunges to 52-Week Low: Analyst Downgrades Pile Up

Key Takeaways

• Shares touched a 52-week bottom at $59.32, shedding more than 37% in 2024
• First-quarter sales of $5.2 billion exceeded projections, yet annual earnings outlook was trimmed
• Investors reacted negatively to the Penumbra purchase priced at $374 per share
• Company faces intensifying competition in the pulsed field ablation market segment
• Wall Street analysts slashed price objectives while maintaining predominantly positive ratings

Shares of Boston Scientific reached their lowest point in a year at $59.32 during Monday’s trading session, marking the culmination of a difficult period that has erased more than 37% of the stock’s value since the beginning of January.

Boston Scientific Corporation, BSX

The dramatic decline stems from several critical developments that unfolded in rapid succession.

The company first revealed its planned acquisition of Penumbra, a medical device manufacturer specializing in neurovascular and peripheral vascular technologies. With a purchase price set at $374 per share, market participants expressed significant displeasure with the transaction terms.

Subsequently, the first quarter financial results were released. While the headline figures appeared solid — revenues reached $5.2 billion, representing an 11.6% increase from the prior year period, and adjusted earnings per share of $0.80 surpassed expectations — leadership revised downward its full-year organic revenue growth projection to a range of 6.5–8.0%, below previous estimates. The adjusted earnings per share forecast for the complete fiscal year was also reduced.

This recalibration of expectations triggered widespread analyst response.

Wall Street Slashes Price Objectives

Truist Securities reduced its price objective from $90 down to $85. Canaccord implemented the most aggressive revision, cutting its target from $109 all the way to $71. RBC Capital adjusted downward from $105 to $100, while Jefferies moved from $110 to $100. BTIG lowered its projection to $80 from a previous $90.

Notably, despite these reductions, the majority of these investment firms maintained their Buy or Outperform recommendations on BSX.

Management also unveiled a $2 billion stock buyback initiative scheduled for the second quarter, potentially establishing support levels for the shares.

Competitive Headwinds in PFA Segment

Among the most significant challenges confronting Boston Scientific currently is deteriorating competitive positioning in the pulsed field ablation sector. The organization is ceding market share to rivals in a category where it previously maintained a dominant presence.

The Penumbra combination is additionally generating operational challenges. Integrating an acquisition of this magnitude requires considerable time, and initial indicators suggest the process faces complications.

BSX currently trades at a forward price-to-earnings ratio of approximately 17.79x. Twelve months earlier, that metric stood near 37x. This represents a substantial valuation compression over a relatively brief timeframe.

InvestingPro calculates BSX’s Fair Value at $74.84, implying the shares may be underpriced relative to underlying business fundamentals. The stock’s PEG ratio registers at 0.34, which certain market observers identify as a potential signal of undervaluation.

A historical pattern merits attention: examining rolling 10-week intervals dating back to 2004, BSX has generated positive returns approximately 52.8% of the time. During periods of sustained downward pressure — similar to current conditions — that probability increases modestly to roughly 54%.

Projections based on this analytical framework place BSX within a $59 to $64 range over the upcoming 10-week period, with the highest probability outcome near $62.

The latest trading data shows BSX settled at $59.32 on Monday, representing its weakest closing price in twelve months.

The post Boston Scientific (BSX) Stock Plunges to 52-Week Low: Analyst Downgrades Pile Up appeared first on Blockonomi.